• Loading stock data...

EKIMAS CORPORATION COMPLETES THE EXERCISE OF WARRANTS

Las Vegas, Nevada. March 8, 2023…EKIMAS Corporation (OTC PINK: ASNB) (“EKIMAS” or the “Company”) and its wholly-owned subsidiary, Nordicus Partners A/S (“Nordicus”), a financial consulting company specializing in providing Nordic companies with the best possible conditions to establish themselves on the U.S. market, today announced the exercise of 115,000 warrants at $1.00 per common share. The warrants were exercised on February 14, 2023 The exercised warrants were part of an original grant of 6,000,000 warrants made in April 2022 to a private investor that is a major shareholder of EKIMAS.

Henrik Rouf, the company’s CEO, stated: “This injection of capital is pivotal in executing EKIMAS’ and Nordicus’ short- and long-term strategic plans. The initial tranche of $115,000 received from the Company’s largest shareholder, provides us with the working capital to continue expanding our presence in the U.S. Additional funding anticipated from the exercise of the remaining warrants should provide the resources necessary to our team and brand in the Nordic region as well as the U.S.”

About Nordicus Partners A/S

Nordicus Partners A/S is a Denmark-based financial consulting company and wholly-owned subsidiary of EKIMAS Corporation, specializing in providing Nordic companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. The company’s core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities, such as: business valuations, growth strategies, attracting capital for businesses & company acquisitions and sales.

 

Forward-Looking Statements

The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forwardlooking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or

contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business

model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because

of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Current Report on Form 8-K relating to the reverse acquisition and related transactions which was filed with the SEC on March 1, 2023. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

 

For further information contact:

Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a masters degree in Auditing and Accounting from the Copenhagen Business School.

Andrew Ritter

Member, Board of Directors

Mr. Ritter is a seasoned healthcare executive with over two decades of leadership experience across biotechnology, digital health, and other healthcare technologies. He has successfully led multiple company exits, taken a company public on NASDAQ, and advised leading private equity and venture capital firms throughout the investment lifecycle.

He began his career as the founder and CEO of Ritter Pharmaceuticals, a microbiome-based biotech company. Over 17 years, he advanced the company from early-stage development through Phase III clinical trials, led its IPO onto the NASDAQ, and later merged the company with QualigenTherapeutics. Following that success, Mr. Ritter led a turnaround and successful exit of Docbot, an AI-driven MedTech company. He is currently an Entrepreneur in Residence at Khosla Ventures, and serves as CEO of portfolio company Cairns Health, an AI-powered remote care solutions to support Home and Senior Care.

He has also served as a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth. Mr. Ritter holds a B.A. in Political Science from the University of Southern California and an M.B.A. from the Wharton School of the University of Pennsylvania.